Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines

@article{Huang2021NeutralizationOS,
  title={Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines},
  author={Baoying Huang and Lianpan Dai and Hui Wang and Zhong-yu Hu and Xiaoming Yang and Wenjie Tan and George Fu Gao},
  journal={bioRxiv},
  year={2021}
}
Recently, the emerged and rapidly spreading SARS-CoV-2 variant of concern (VOC) 501Y.V2 with 10 amino acids in spike protein were found to escape host immunity induced by infection or vaccination. Global concerns have been raised for its potential to affect vaccine efficacy. Here, we evaluated the neutralization activities of two vaccines developed in China against 501Y.V2. One is licensed inactivated vaccine BBIBP-CorV and the other one is recombinant dimeric receptor-binding domain (RBD… Expand
Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques
TLDR
RFN, adjuvanted with a liposomal-QS21 formulation (ALFQ), elicits humoral and cellular immune responses exceeding those of current vaccines in terms of breadth and potency and protects against high-dose respiratory tract challenge. Expand
Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques
TLDR
The evaluation of a ferritin nanoparticle vaccine displaying the receptor-binding domain of the SARS-CoV-2 spike protein (RFN) adjuvanted with Army Liposomal Formulation QS-21 (ALFQ) supports consideration of RFN for vaccine development against multiple concerning members of the Sarbecovirus subgenus of Betacoronaviruses. Expand
RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates
  • Xiaoyan Pan, Jian Shi, +28 authors Gengfu Xiao
  • Medicine
  • Cell discovery
  • 2021
TLDR
A novel RBD homodimer vaccine developed as a SARS-CoV-2 vaccine candidate elicited strong immune response in both rodents and non-human primates and may serve as a safe, effective, and low-cost Sars- CoV- 2 vaccine candidate. Expand
Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines
TLDR
This review summarizes with a critical view the molecular aspects associated with the interaction of SARS-CoV-2 RBD with its receptor in human cells, the angiotensin-converting enzyme 2 (ACE2), the epitopes involved in the neutralizing activity, and the impact of virus mutations thereof. Expand
The Genetic Variant of SARS-CoV-2: would It Matter for Controlling the Devastating Pandemic?
TLDR
This review summarized the current understanding on five notable genetic variants, i.e., D614G, Cluster 5, VOC 202012/01, 501Y.V2 and P.1, and discussed the potential impact of these variants on the virus transmission, pathogenesis and vaccine efficacy. Expand
SARS-CoV-2 variants, spike mutations and immune escape
TLDR
The literature on mutations of the SARS-CoV-2 spike protein, the primary antigen, is summarized, focusing on their impacts on antigenicity and contextualizing them in the protein structure, and discussed in the context of observed mutation frequencies in global sequence datasets. Expand
Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies
TLDR
The effects of reported variants on neutralizing antibodies and the protective efficacy of different vaccines are analyzed and strategies for applying current vaccines against variants and developing next-generation vaccines are proposed. Expand
Comprehensive mapping of neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination
TLDR
The findings indicate that the antibody response established by natural infection or vaccination might be able to effectively neutralize B. 1.1.1, and standardized protocols for neutralization assays, as well as updating immune-based prevention and treatment, are needed. Expand
The way of SARS-CoV-2 vaccine development: success and challenges
  • Yetian Dong, Tong Dai, +6 authors Fangfang Zhou
  • Medicine
  • Signal Transduction and Targeted Therapy
  • 2021
TLDR
The influence of mutational hotspots on the vaccine efficacy and characteristics of variants of interest and concern are summarized and the duration of immune responses after natural infection or vaccination after SARS-CoV-2 infection is provided. Expand
The rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistance
The causative factor of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuously mutating. Interestingly, identified mutations mainly occur in the spike (S) proteinExpand
...
1
2
3
4
...

References

SHOWING 1-10 OF 15 REFERENCES
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
TLDR
Two-dose immunizations using 2 μg/dose of BBIBP-CorV provided highly efficient protection against SARS-CoV-2 intratracheal challenge in rhesus macaques, without detectable antibody-dependent enhancement of infection. Expand
mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants
TLDR
Low neutralization from convalescent serum by pseudovirus neutralization (PsVN) assays and resistance to certain monoclonal antibodies is found in subjects immunized with Moderna mRNA-1273 and despite the observed decreases, the GMT of VSV PsVN titers in human vaccinee sera against the B.1.1 .1.351 variant remained at ~1/300. Expand
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
TLDR
It is shown that pseudovirus expressing 501Y.V2 spike protein completely escapes three classes of therapeutically relevant antibodies and exhibits substantial to complete escape from neutralization, but not binding, by convalescent plasma. Expand
Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization
TLDR
The Covid-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2, continues to rage, and new variants with similar spike mutations present new challenges for mAb therapy and threaten the protective efficacy of current vaccines. Expand
A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS
TLDR
A dimeric form of MERS-CoV RBD is described that overcomes limited immunogenicity and significantly increased neutralizing antibody (NAb) titers compared to conventional monomeric form and protected mice against MSPV infection. Expand
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
TLDR
The primary outcomes were safety and tolerability and immunogenicity, assessed as the neutralising antibody responses against infectious SARS-CoV-2, and no serious adverse event was reported within 28 days post vaccination. Expand
Viral targets for vaccines against COVID-19
TLDR
As the world races to develop vaccines against SARS-CoV-2, Dai and Gao highlight which viral targets are best to include in a vaccine and how this impacts the induced immune response and the safety and efficacy of a vaccine. Expand
A Novel Coronavirus from Patients with Pneumonia in China, 2019
TLDR
Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily, which is the seventh member of the family of coronaviruses that infect humans. Expand
Reemergent Cases of COVID-19 — Xinfadi Wholesales Market, Beijing Municipality, China, June 11, 2020
TLDR
The genome sequences of these Xinfadi strains provide strong evidence that the reemergent of COVID-19 cases in Beijing may be caused by an imported source of infections, suggesting that it is not continuous transmission of the local CO VID-19 virus strain. Expand
Determination of 50% endpoint titer using a simple formula.
TLDR
In this paper, a simple formula/method for calculating 50% endpoints has been proposed and yields essentially similar results as those of the Spearman-Karber method. Expand
...
1
2
...